Most recent update: Thursday, November 30, 2017 - 11:56

Bariatric News - Cookies & privacy policy

You are here

Congress announcement

Seminal metabolic and diabetic surgical conference in London

The 3rd World Congress is a comprehensive, multidisciplinary forum where leading international experts will conduct a critical review and discussion of the latest research findings on metabolic/bariatric surgery
The aim of the 2nd Diabetes Surgery Summit is to assist leading diabetes organisations in the development of new guidelines for multimodality diabetes care

In September this year, London will host two seminal events that will be witness to an unprecedented gathering to review the latest research in metabolic surgery and to develop new guidelines for the development of a modern, multi-modality approach to the care of type 2 diabetes - The 3rd World Congress on Interventional Therapies for Type 2 Diabetes and the 2nd Diabetes Surgery Summit.

The 3rd World Congress on Interventional Therapies for Type 2 Diabetes is a comprehensive, multidisciplinary forum where leading international experts will conduct a critical review and discussion of the latest research findings on metabolic/bariatric surgery and novel interventional therapies for type 2 diabetes.

Francesco Rubino

“Over the past decade, clinical and experimental research has shown that such powerful anti-diabetes effect results from changes in various aspects of gastrointestinal physiology, revealing a crucial and previously underappreciated role of the gut in glucose metabolism,” said Congress Chairman, Professor Francesco Rubino (King’s College London, UK). “This new knowledge challenges traditional paradigms of disease and may provide clues for the discovery of the yet elusive causes of this illness. The 3rd World Congress will examine the latest data and try to identify the exact mechanisms by which surgery controls diabetes. It is hoped that by advancing this knowledge, we may reveal new targets for future, less invasive interventional therapies and novel pharmaceuticals.”

The programme will include state-of-the art invited lectures and debates among clinicians, scientists, and policy makers. The congress also welcomes submission of original abstracts on subjects such as clinical outcomes, mechanisms of action and cost-effectiveness of metabolic surgery, new device-based therapies of obesity and diabetes, gastrointestinal physiology and its role in glucose metabolism (for a complete list of abstracts, please see the list below).

“The overarching aim of the congress is to craft an agenda of research priorities and health policy initiatives,” explained Rubino. “As a result, the Congress has been designed for professionals in the fields of endocrinology, diabetes, bariatric/ metabolic surgery, cardiology, epidemiology, gastroenterology, internal medicine, family medicine, pharmacology, nutrition, basic science, and public health, as well as allied health professionals, policy makers, and scientists from pharmaceutical and medical device industries.”

The meeting has already received endorsement from the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the national diabetes associations of UK and China, as well as the British Obesity and Metabolic Surgical Society (BOMSS) and the National Obesity Forum. It is expected that several addition surgical and medical organisations will endorse the meeting.

2nd Diabetes Surgery Summit (DSS-II)

The aim of the 2nd Diabetes Surgery Summit, (DSS-II) is to assist leading diabetes organisations in the development of new guidelines for multimodality diabetes care.

“The DSS-II is a consensus conference aimed at the development of guidelines and recommendations for a modern, multimodality approach to the care of diabetes,” he explained. “The first Diabetes Surgery Summit was held in Rome, Italy in March 2007. It was the first conference specifically aimed at establishing recommendations regarding gastrointestinal operations to intentionally treat T2DM and it is widely recognised as a seminal event for the development of the concept and practice of metabolic and diabetes surgery.”

Specific themes of the World Congress/DSS-II include

  • Development of new recommendations/ guidelines for integrated, multimodality treatment of type 2 diabetes - DSS-II
  • Epidemiology and economic impact of diabetes
  • Impact of metabolic surgery on cardiovascular risk
  • Role of integrated surgical and medical approaches for diabetes (multimodality therapies)
  • Mechanisms of action of bariatric and metabolic surgery
  • Novel technologies and gastrointestinal devices for diabetes
  • Cost effectiveness of surgery as a treatment of diabetes
  • Addressing barriers to proper health care utilization: beyond stigma, misconceptions and discrimination
  • Developing adequate health policies for improved, equitable access to surgery
  • Role of the gastrointestinal tract in glucose metabolism
  • Gut hormones, microbiota, bile acids, nutrient sensing and intestinal glucose metabolism in physiology, obesity and diabetes
  • Challenging conventional paradigms of diabetes and obesity: a debate by leading scientists in the field
  • How the study of the mechanisms of surgical control of diabetes can lead to the discovery of novel targets for drug development

The DSS-II is organized in partnership with the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), Diabetes UK and the Chinese Diabetes Society (CDS). Prior to the meeting in London, a group of experts that includes official representatives of leading diabetes organizations will develop draft guidelines based on evidence from a systematic review of available literature, using the Delphi method of consensus conferences. Proposed guidelines and supporting evidence will then be presented during dedicated plenary sessions of the 3rd world congress on interventional therapies in London. These proposals and their supporting evidence will be presented during dedicated sessions of the world congress for further debate and input by both invited experts and general attendees. Voting delegates will establish final guidelines/recommendations through a final vote on the last day of the conference.

“The new guidelines are intended to guide endocrinologists, primary care physicians and surgeons in the selection of candidates for surgical treatment and in the development of a diabetes-based model for pre- and post-operative care,” said Rubino. “A specific subject of the DSS-II will be the development of a rational approach to the integration of pharmaceutical and surgical therapies to improve outcomes. DSS-II will also craft an agenda of research priorities and health policy initiatives aimed at improving access to surgical and interventional therapies.”

 “Attendance of this truly historical event will provide a unique opportunity to get abreast of the science behind metabolic surgery and to participate in initiatives that will expand the horizons of diabetes care and research for years to come, added Rubino. “On behalf of the organising committee and myself, I look forward to welcoming you to London for this exciting and memorable event.”

Abstracts topics for the 3rd World Congress on Interventional Therapies for Type 2 Diabetes 

  • Cost effectiveness of surgery as a treatment of diabetes
  • Effects of bariatric/metabolic surgery on diabetes-related complications
  • Epidemiology and economic impact of diabetes
  • Impact of bariatric/metabolic surgery on cardiometabolic risk
  • Impact of bariatric/metabolic surgery on glycemic control
  • Integration of pharmaceutical/surgical therapies and optimisation of glycemic control post-surgery
  • Intestinal glucose metabolism and nutrient sensing
  • Mechanisms of action of bariatric and metabolic surgery
  • Novel technologies and gastrointestinal devices for diabetes
  • Randomized clinical trials comparing surgery vs medical treatment for diabetes
  • Randomized clinical trials comparing surgical procedures head to head for the treatment of diabetes
  • Role of bile acids in glucose homeostasis
  • Role of gut microbiota in metabolism and in the pathophysiology of obesity and diabetes
  • Role of the gastrointestinal tract in glucose metabolism
  • Safety of bariatric/metabolic surgery

If you are interested in submitting an abstract and for more information about the congress, including how to register, please cick here

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.